24 research outputs found

    Progress of Hepatitis C elimination in Viennese people living with HIV after two decades of increasing cure rates

    No full text
    Interferon(IFN)-based hepatitis C virus (HCV) therapy has been replaced by direct-acting antivirals (DAAs). We assessed temporal trends in patient characteristics, transmission risks, treatment initiation, and cure rates in eras of IFN, restricted DAA-access, and unrestricted DAA-access in Viennese HCV/HIV-coinfected patients (HIV/HCV). Consecutive HIV/HCV-coinfected patients starting HCV treatment at the Vienna General Hospital between 2002 and 2020 were retrospectively enrolled. Of all N = 508 HIV/HCV, 78% (398/508) were male and the mean age was 41.8 ± 9.5 years. ‘People-who-inject-drugs’ (PWID) accounted for 61% (311/508), while 31% (156/508) were ‘men who have sex with men’ (MSM). In the IFN-era, restricted DAA-era and unrestricted DAA-era, N = 152, N = 129, and N = 227 HCV treatments were started and 49% (74/152), 95% (122/129), and 88% (200/227) achieved sustained virologic response, respectively. Treatment during the IFN-era was a strong predictor for virologic non-response (aOR 12.69; 6.93–23.24) and loss-to-follow-up (aOR 6.12; 2.99–12.54), while virologic non-response was less common in ‘MSM’ (aOR 0.28; 0.13–0.62). Ninety three percent (50/54) of the observed HCV reinfections occurred in the unrestricted DAA-era. A substantial increase in ‘MSM’ transmission was observed since 2010 with 66% (107/161) in the DAA-era versus 15% (49/330) prior to the DAA-era. HCV cure rates in Viennese HIV patients increased from 49% in the IFN-era to 88–95% in the DAA-era. MSM-related risk behaviour and reinfections became the key challenges towards HCV elimination in HIV-coinfected patients.</p

    The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection - Fig 2

    No full text
    <p><b>A:</b> Proportion of patients with METAVIR F3/F4 according to PNPLA3-SNP. <b>B:</b> Fibrosis progression rate according to PNPLA3-SNP. <b>C:</b> Levels of aminotransferases according to PNPLA3 genotype. <b>D:</b> Portal pressure (HVPG) according to PNPLA3 genotype. <b>E:</b> Hepatic steatosis (assessed by CAP) according to PNPLA3 genotype. <b>F:</b> Levels of y-glutaryl transaminases according to PNPLA3 genotype. Abbreviations: PNPLA3 (patatin-like phospholipase domain-containing protein 3), SNP (single nucleotide polymorphism), HVPG (hepatic venous pressure gradient), CAP<sup>™</sup> (Controlled Attenuation Parameter).</p

    Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy

    No full text
    <div><p>Background and Aims</p><p>Monitoring of chronic Hepatitis C (CHC) treatment relies on HCV RNA quantification by means of real-time PCR methods. Assay specific analytical sensitivities may impact therapy management.</p><p>Methods</p><p>Comparative analysis between three commercial assays (Roche COBAS AmpliPrep/COBAS TaqMan Version 1 (CAP/CTM Ver. 1), Version 2 (CAP/CTM Ver. 2) and the Abbott RealTime HCV (ART) assay) was performed on 247 available samples taken at key decision time points during antiviral therapy of 105 genotype 1 patients (triple therapy: n = 70; dual therapy: n = 35).</p><p>Results</p><p>Overall concordance of HCV RNA measurements was high between the two Roche systems (89%; n = 220/247) but lower between the Roche assays and the ART (CAP/CTM Ver. 1 vs ART: 77.3%; n = 191/247 and CAP/CTM v.2 vs ART: 80.1%; n = 198/247). Most discrepancies were noted in week 4/8 samples with residual viremia (</p><p>Conclusion</p><p>An abbreviated course of treatment can safely be applied in patients with residual viremia (</p></div

    Shortening of antiviral therapy (triple therapy regimen) according to assay specific detection of HCV RNA (n = 13).

    No full text
    <p>According to the routine assay for guidance of treatment response (Roche COBAS AmpliPrep/COBAS TaqMan HCV quantitative assay Version 1 (CAP/CTM Ver. 1) 13 patients underwent an abbreviated course of antiviral therapy (24 weeks). In comparison: number and therapy outcome of patients who would have been eligible for a shortening of antiviral treatment according to the results of the Roche COBAS AmpliPrep/COBAS TaqMan HCV quantitative assay Version 2 (CAP/CTM Ver. 2), according to the Abbott RealTime HCV assay (ART) and the adapted version of the ART Abbott RealTime HCV assay (column ART adapted: shortening of antiviral treatment also in cases where HCV RNA was detected but </p

    Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial

    No full text
    <p>Article full text</p> <p>The full text of this article can be found at <u>https://link.springer.com/article/10.1007/s40121-016-0110-5</u></p><p><u><br></u></p><p></p> <p>Provide enhanced content for this article</p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p>Other enhanced features include, but are not limited to:</p> <ul> <li>Slide decks</li> <li>Videos and animations</li> <li>Audio abstracts</li> <li>Audio slides</li> </ul

    Supplemental material for Liver disease in adults with α1-antitrypsin deficiency

    No full text
    <p>Supplemental material for Liver disease in adults with α1-antitrypsin deficiency by Mattias Mandorfer, Theresa Bucsics, Veronika Hutya, Karin Schmid-Scherzer, Benedikt Schaefer, Heinz Zoller, Arnulf Ferlitsch, Markus Peck-Radosavljevic, Michael Trauner, Peter Ferenci, Meinhard Kneussl and Thomas Reiberger in United European Gastroenterology Journal</p

    Virological response to PEGIFN/RBV by PNPLA3-SNP and IL28B-SNP.

    No full text
    <p>Virologic response rates (rapid virological response, complete early virological response and sustained virological response) to PEGIFN/RBV by PNPLA3-SNP and IL28B-SNP; reported as number (percentage) of patients; Abbreviations: PNPLA3 (patatin-like phospholipase domain-containing protein 3), IL28B (interleukin 28B), RVR (rapid virological response), cEVR (complete early virological response), SVR (sustained virological response).</p><p>Virological response to PEGIFN/RBV by PNPLA3-SNP and IL28B-SNP.</p

    Enrollment and patient disposition.

    No full text
    <p><sup>a</sup>Other reasons (more than one reason may apply to a given patient): no final confirmation from the investigator (n = 56); contraindications to therapy (n = 15); HCV RNA-negative at screening/baseline (n = 12); end-stage renal disease (n = 7); major organ transplantation (n = 2); not treated with peginterferon alfa (n = 1) or ribavirin (n = 2); acute hepatitis C (n = 1); co-infection with HIV (n = 115); co-infection with HBV (n = 74); treatment with regimen other than peginterferon alfa-2a/ribavirin or peginterferon alfa-2b/ribavirin (n = 14); treatment-naive and intended treatment duration of 72 weeks (n = 6).</p
    corecore